Reducing soluble urokinase receptor in the circulation
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 16, 2018
Issued Date -
N/A
app pub date -
May 9, 2012
filing date -
May 9, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Focal segmental glomerulosclerosis (FSGS) is a common cause of proteinuric kidney disease, which comprises both native and transplanted kidneys. Treatment was limited in the past due to the complicated pathogenesis of FSGS, including previously unidentified serum factors. Here, serum soluble urokinase receptor (suPAR) is reported to be elevated in FSGS patients but not in patients with other primary glomerular diseases. Higher pre-transplantation suPAR levels are associated with risk for FSGS recurrence in kidney grafts. Renal disease only develops when suPAR sufficiently activates podocyte β3 integrin. Thus, disease pathogenesis can be stopped or slowed by ex vivo removal of suPAR from a subject's circulation. Removal may be measured by comparing the level (e.g., amount or concentration) of suPAR before and after such treatment.
First Claim
Other Claims data not available
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jul 16, 2025 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jul 16, 2029 |
